Drug Profile

Research programme: ulcerative colitis therapeutic - BenevolentAI

Alternative Names: Ulcerative colitis - BenevolentAI

Latest Information Update: 01 Nov 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BenevolentAI
Class Anti-inflammatories; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Ulcerative colitis

Most Recent Events

19 Oct 2021 Research programme: ulcerative colitis therapeutic - BenevolentAI is available for licensing as of 19 Oct 2021. https://www.benevolent.com/partnering
14 Oct 2021 Preclinical trials in Ulcerative colitis in United Kingdom (PO) .
14 Oct 2021 BenevolentAI plans a phase I trial for Ulcerative colitis in early 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com